Researchers identify Sirt1 as target in aggressive prostate cancer

A new study points to a possible intervention point in one of prostate cancer’s toughest forms

Researchers at Columbia University Irving Medical Center say they have identified a gene that drives the development of neuroendocrine prostate cancer, or NEPC, an aggressive form of the disease that can emerge after standard treatment stops working. Their study, published in the Journal of Experimental Medicine, found that genetic or pharmacological inhibition of Sirtuin 1, or Sirt1, prevented the growth of NEPC tumors in mice.

The finding matters because NEPC remains one of the most difficult prostate cancer states to treat. Standard care for prostate cancer typically relies on androgen deprivation therapy, which suppresses the hormonal signals many tumors need to grow. But over time, some cancers recur in a more aggressive, treatment-insensitive form. Understanding how that transition happens has been a major unresolved problem in the field.

What the researchers found

The Columbia-led team used a genetic screen in mice to look for mutations that appeared repeatedly across independent prostate cancer tumors. From 75 candidate genes linked to NEPC development, Sirt1 emerged as the most promising. The researchers then examined its role in a human prostate cancer cell line and found that inducing the NEPC state increased the expression of genes predicted to be activated by Sirt1.

That does not make Sirt1 a simple on-off switch for the disease, but it does suggest the gene occupies a meaningful position in the molecular program that helps prostate tumors shift into this more dangerous lineage. The study’s central implication is that Sirt1 may be helping drive the plasticity that lets tumors escape therapies that once worked.

That concept of lineage plasticity is crucial. It refers to the ability of cancer cells to change identity or behavior in ways that allow them to survive treatment. In prostate cancer, that shift can produce a variant that no longer responds to the androgen-targeting strategies that define current care. If Sirt1 helps govern that transformation, it becomes a valuable target for drug development.

Why Sirt1 stands out

Sirt1 encodes an enzyme involved in a wide range of cellular functions, including gene expression and metabolism. That broad role is part of what makes it scientifically interesting. Cancer progression often depends on systems that do not just control one pathway, but coordinate multiple survival programs at once. A regulator like Sirt1 may therefore offer leverage over a wider disease process rather than a single downstream effect.

The mouse data give the study its strongest practical edge. The researchers report that both genetic silencing and pharmacological inhibition of Sirt1 prevented NEPC tumor growth in mice. That is important because it moves the work beyond association and into intervention. It suggests that Sirt1 is not merely present in aggressive tumors; it may be functionally necessary for them to develop or persist.

Even so, the path from a mouse study to a human therapy is long. Many promising oncology targets fail to translate into clinically useful drugs. That is especially true when a target is involved in broad biological functions, which can raise questions about side effects, dosing windows, and patient selection. The study does not resolve those issues, but it does provide a clearer rationale for pursuing them.

What this could mean for patients

The current importance of the work lies less in an immediate treatment change than in a sharper map of the disease. NEPC is feared because it often emerges after the apparent logic of treatment has broken down. A tumor that once depended on one biological program adapts into another. Identifying a molecule linked to that shift creates an opportunity to intervene earlier, delay the transition, or perhaps treat the transformed cancer more effectively once it appears.

That is the broader promise behind the study’s conclusion that it lays groundwork for future clinical studies. If Sirt1 inhibition can be refined into a therapeutic strategy, the target could become part of a new approach to preventing or managing NEPC. It could also help researchers build better diagnostic tools for identifying which tumors are most at risk of making the transition.

For now, the study adds weight to a growing view of cancer as a disease of adaptation as much as uncontrolled growth. Tumors survive by changing. Therapies succeed when they can limit that ability. In this case, Sirt1 may prove to be one of the mechanisms prostate cancer uses to reinvent itself under treatment pressure.

That does not yet make it a clinical answer. But it does make it one of the more concrete new leads in the effort to stop one of prostate cancer’s most aggressive forms before it gains ground.

This article is based on reporting by Medical Xpress. Read the original article.